IN 1130 |
| Catalog No.GC50317 |
IN 1130 es un inhibidor de la cinasa del receptor tipo I del factor de crecimiento transformante β (ALK5) altamente selectivo con una IC50 de 5,3 nM para la fosforilación de Smad3 mediada por ALK5.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 868612-83-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Potent and selective inhibitor of TGF-β type I receptor (ALK5). Inhibits Smad-2 phosphorylation (IC50 = 5.3 nM). Exhibits selectivity over a panel of 27 serine/ threonine and tyrosine kinases including P38α. Attenuates TGFβ/Smad signaling, cell migration, invasion, lung metastasis and increases survival of mice in 4TI in vivo models. Suppresses renal fibrosis in obstructive nephropathy in vivo models.
Moon et al (2006) IN-1130, a novel transforming growth factor-beta type I receptor kinase (ALK5) inhibitor, suppresses renal fibrosis in obstructive nephropathy. Kidney Int. 70 1234 PMID:16929250 |Lee et al (2008) Effect of IN-1130, a small molecule inhibitor of transforming growth factor-beta type I receptor/AVNreceptor-like kinase-5, on prostate cancer cells. J.Urol. 180 2660 PMID:18951571 |Park et al (2014) An novel inhibitor of TGF-beta type I receptor, IN-1130, blocks breast cancer lung metastasis through inhibition of epithelial-mesenchymal transition. Cancer Lett. 351 72 PMID:24887560
Average Rating: 5 (Based on Reviews and 13 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *